[Inhaled budesonide for severe asthma at high altitude]

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Altitude Physiology

Background:

• Severe asthma presents unique challenges, particularly at high altitudes where hypoxia can exacerbate respiratory distress.
• Standard asthma treatments may have limited efficacy in high-altitude environments, necessitating specialized therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy of high-dose inhaled budesonide combined with terbutaline in managing severe asthma exacerbations at high altitudes.
• To assess the impact of this combination therapy on clinical asthma indices and pulmonary function tests.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 42 patients with severe asthma at high altitude.
• Participants received either budesonide (1.2 mg) plus terbutaline (2.5 mg) or terbutaline (2.5 mg) with placebo via metered-dose inhalers, administered twice.
• Clinical assessments included accessory respiratory muscle activity, dyspnea, wheezing, and lung function (FEV1%, PEF%) before and up to 6 hours after treatment.

Main Results:

• The budesonide group showed significant improvements in FEV1% (up to 67% at 6 hours) and PEF% (up to 69% at 6 hours) compared to baseline (P < 0.01).
• The clinical index significantly decreased in the budesonide group (from 8.3 to 2.5 at 6 hours, P < 0.01), indicating reduced asthma severity.
• The control group receiving terbutaline alone showed minimal changes in lung function and clinical index.

Conclusions:

• High-dose inhaled budesonide combined with terbutaline is an effective treatment for severe asthma in high-altitude patients.
• Therapeutic benefits, including improved lung function and reduced symptoms, are observed as early as 2 hours post-administration.